engleski

EFFECTIVE PHARMACOGENOMIC-DRIVEN TREATMENT OF MAJOR DEPRESSION: A CASE REPORT

Major depressive disorder (MDD) is a complex disorder that can affect patients’ ability to sleep, work, eat, and do daily practice. It affects approximately 1 in 5 adults at least once in a lifetime (Weihs & Wert 2011). Up to a third of MDD patients have treatment- resistant depression (TRD) (Al-Harbi 2012). TRD is associated with increased suicide risk, sexual dysfunction, greater depression severity and body mass index •30 kg/m2 (Saragoussi et al. 2017). Since genetic variants explain up to 42% of interindividual differences in antidepressant response, more precise and personalized way of MDD and TRD treatment such as pharmacogenomics (PGx) is necessary to improve outcomes and safety, and to reduce the economic burden of 136 billion USD annually in the United States alone associated with adverse drug reactions (Han et al. 2018, Johnson & Bootman 1995).

hrčak, hrcak, znanstveni časopisi, hrvatski, scientific journals, croatian

nije evidentirano